Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ESST | ISIN: US6085502085 | Ticker-Symbol:
NASDAQ
21.11.24
18:35 Uhr
0,374 US-Dollar
-0,014
-3,51 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULAR TEMPLATES INC Chart 1 Jahr
5-Tage-Chart
MOLECULAR TEMPLATES INC 5-Tage-Chart

Aktuelle News zur MOLECULAR TEMPLATES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrMolecular Templates, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB1
MOLECULAR TEMPLATES Aktie jetzt für 0€ handeln
14.10.Why Molecular Templates (MTEM) Stock Is Down 77% Today25
11.10.Molecular Templates, Inc. - 8-K, Current Report4
04.10.Molecular Templates, Inc. - 8-K, Current Report1
27.09.Molecular Templates hält Jahreshauptversammlung ab22
27.09.Molecular Templates, Inc. - 8-K, Current Report2
10.09.MTEM stock touches 52-week low at $1 amid market challenges9
14.08.Molecular Templates, Inc. - 10-Q, Quarterly Report2
14.08.Molecular Templates, Inc. - 8-K, Current Report1
14.08.Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update136Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy...
► Artikel lesen
03.06.Molecular Templates, Inc. Provides Interim Update285Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting...
► Artikel lesen
03.06.Molecular Templates, Inc. - 8-K, Current Report4
15.05.Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update210AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and...
► Artikel lesen
09.04.Molecular Templates, Inc.: Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced164AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and...
► Artikel lesen
29.03.Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update281AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and...
► Artikel lesen
04.03.Molecular Templates, Inc. Provides Interim Update279AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and...
► Artikel lesen
13.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 44.738The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS42328V8019 HELIUS...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1